Heartseed Inc.

The Company is in the research and development stage and continues to record operating losses; operating cash flow will remain negative until developed products are launched. Commercialization requires substantial expenditures for research and development, clinical trials, obtaining regulatory approvals, and building manufacturing and sales systems, and the timing of funding needs is difficult to predict. While the Company works to secure funds primarily through capital increases, along with bank loans, commitment lines, and subsidies, if sufficient funds cannot be secured when needed, this may have a material impact on the Company's financial condition and business development.

The Company positions the conditional and time-limited approval system under the Pharmaceuticals and Medical Devices Act as its most important strategy, but under this system, post-marketing surveillance is required after launch. If efficacy or safety is judged insufficient during the surveillance period, if unexpected adverse events occur, or if there are differences in views with regulatory authorities or the number of cases falls short of the target, there is a risk that full approval may not be obtained or that conditional approval may be revoked. Such events could have a material impact on the Company's operating results and business development.

During the clinical trial stage and after market launch, unexpected quality issues or adverse events may occur with regenerative medicine products. The Company plans to address this through outsourcing manufacturing to a CDMO, establishing a reliability assurance department, and obtaining liability insurance; however, if the amount of damages exceeds the insurance coverage, or if negative publicity arises from product liability claims, this could lead to product recalls, discontinuation of sales, or the need for additional testing, resulting in decreased sales and substantial costs, which could have a material impact on the Company's operating results and business development.

There is a risk both that the Company's patents may be infringed by third parties and that the Company may infringe on third-party patent rights. There is no guarantee that patents under application will be granted, and if the Company unintentionally infringes on another company's intellectual property rights, it may face demands to cease manufacturing and sales or claims for substantial damages. In addition, if licenses granted by public institutions or joint research partners are lost, this could hinder business continuity and have a material impact on the Company's operating results and business development.

In the fields of regenerative medicine and iPS cells, research competition is progressing on a global scale. If competitors develop innovative technologies, acquire related patents, or achieve earlier market launches, this could result in the Company being unable to sell its products, facing difficulty marketing them, or being unable to cover research and development costs. The trend of increasing entry by major companies, emerging companies, and research institutions continues, and while the Company strives to collaborate with universities and public research institutions and to stay abreast of the latest technological trends, if it loses its competitive advantage, this could have a material impact on the Company's operating results and business development.

Raw materials, reagents, needles, catheters, and other items used in the manufacturing process have limited substitutability. If outsourcing becomes difficult due to changes in the business policies of partner companies, reduced supply capacity, quality deterioration, natural disasters, or other factors, finding alternative suppliers and rebuilding the manufacturing system would require substantial time and cost. Even if alternative suppliers can be secured, the Company may be forced to accept unfavorable contract terms, which could cause significant delays in the development schedule and have a major impact on the business.

While data from the LAPiS trial for HS-001 is nearly complete, HS-005 is at the early stage of the EMERALD trial, and new pipeline candidates are at the early stage of basic research, resulting in high uncertainty regarding commercialization and monetization. If development of new pipeline candidates is discontinued, dependence on revenue from the lead pipeline HS-001 will increase, creating a risk that the Company's operating results will be significantly affected by the development and sales status of this product. Technical difficulties, competition, changes in laws and regulations, personnel shortages, and supply chain uncertainty exist as constraining factors.

The Company is focusing on establishing manufacturing methods, including developing large-scale cell culture technology, but if it becomes difficult to build such systems, there is a risk of delayed supply of investigational drugs and approved products, or of clinical trials being discontinued or withdrawn. When changing manufacturing locations, raw materials, or manufacturing processes, regulatory authorities may require submission of additional data or re-testing. Even after obtaining marketing approval, risks exist that planned sales may not be achieved due to difficulty forecasting supply and demand, patient reluctance, failure to achieve cost-effectiveness, or litigation arising from regulatory violations.

Since there are currently no business partners and the Company cannot receive milestone income or similar payments, it is highly likely that the Company will raise funds primarily through capital increases in connection with future progress, delays, or failures in research and development. In addition, the Company has adopted stock options and restricted stock compensation plans for officers and employees, and if stock acquisition rights are exercised, this could dilute the value of shares per unit. The likelihood is disclosed as high (for stock acquisition rights) and medium (for capital increases), raising concerns about the impact on existing shareholders.

In the LAPiS trial for HS-001 (all 10 cases with 52-week follow-up completed) and the EMERALD trial for HS-005 (14 cases planned in total), there is a risk of unforeseen safety concerns arising or of clinical trial delays or discontinuation due to difficulties in patient recruitment. Delays in the approval application and review process, and research and development costs exceeding expectations, are also of concern. If product launches and research and development activities do not proceed as planned, this could delay, reduce, or result in the loss of sales, potentially affecting the Company's operating results and business development.